These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19343369)

  • 1. Cognitive impairment in men treated with luteinizing hormone-releasing hormone agonists for prostate cancer: a controlled comparison.
    Jim HS; Small BJ; Patterson S; Salup R; Jacobsen PB
    Support Care Cancer; 2010 Jan; 18(1):21-7. PubMed ID: 19343369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
    Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.
    Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
    Int J Clin Oncol; 2015 Oct; 20(5):1018-25. PubMed ID: 25681879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant.
    Marks LS
    Urology; 2003 Dec; 62(6 Suppl 1):36-42. PubMed ID: 14706507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive Function in Patients With Prostate Cancer Receiving Luteinizing Hormone-Releasing Hormone Analogues: A Prospective, Observational, Multicenter Study.
    Morote J; Tabernero ÁJ; Álvarez Ossorio JL; Ciria JP; Domínguez-Escrig JL; Vázquez F; Angulo J; López FJ; de La Iglesia R; Romero J;
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):590-594. PubMed ID: 28581399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003.
    Moul JW; Fowler JE
    Urology; 2003 Dec; 62(6 Suppl 1):20-8. PubMed ID: 14706505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma.
    Townsend MF; Sanders WH; Northway RO; Graham SD
    Cancer; 1997 Feb; 79(3):545-50. PubMed ID: 9028366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy.
    Marumo K; Baba S; Murai M
    Int J Urol; 1999 Jan; 6(1):19-23. PubMed ID: 10221860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
    Sayyid RK; Evans A; Hersey K; Maloni R; Hurtado-Coll A; Kulkarni G; Finelli A; Zlotta AR; Hamilton R; Gleave M; Fleshner NE
    Clin Cancer Res; 2017 Apr; 23(8):1974-1980. PubMed ID: 27756786
    [No Abstract]   [Full Text] [Related]  

  • 14. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
    Pickles T; Hamm J; Morris WJ; Schreiber WE; Tyldesley S
    BJU Int; 2012 Dec; 110(11 Pt B):E500-7. PubMed ID: 22564197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up.
    Akaza H; Homma Y; Usami M; Hirao Y; Tsushima T; Okada K; Yokoyama M; Ohashi Y; Aso Y;
    BJU Int; 2006 Sep; 98(3):573-9. PubMed ID: 16925756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.
    Clinton TN; Woldu SL; Raj GV
    Expert Opin Pharmacother; 2017 Jun; 18(8):825-832. PubMed ID: 28480768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study.
    Potosky AL; Knopf K; Clegg LX; Albertsen PC; Stanford JL; Hamilton AS; Gilliland FD; Eley JW; Stephenson RA; Hoffman RM
    J Clin Oncol; 2001 Sep; 19(17):3750-7. PubMed ID: 11533098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of short-term estradiol therapy on cognitive function in older men receiving hormonal suppression therapy for prostate cancer.
    Taxel P; Stevens MC; Trahiotis M; Zimmerman J; Kaplan RF
    J Am Geriatr Soc; 2004 Feb; 52(2):269-73. PubMed ID: 14728639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
    Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
    Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer.
    van der Sluis TM; van Moorselaar RJ; Meuleman EJ; ter Haar RW; Bui HN; Heijboer AC; Vis AN
    Urology; 2013 May; 81(5):1005-9. PubMed ID: 23465153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.